Compounds > sr141716

Page last updated: 2024-08-26

sr141716 and Nicotine Addiction

sr141716 has been researched along with Nicotine Addiction in 20 studies

Research

Studies (20)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	15 (75.00)	29.6817
2010's	5 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Forget, B; Gamaleddin, I; Goldberg, SR; Guranda, M; Le Foll, B	1
Bergman, J; Goldberg, SR; Justinova, Z; Le Foll, B; Makriyannis, A; Redhi, GH; Schindler, CW; Vemuri, K	1
Antoniou, K; Delis, F; Gueye, AB; Laviolette, SR; Le Foll, B; Loureiro, M; Makriyannis, A; Poulia, N; Pryslawsky, Y; Trigo, JM; Vemuri, K	1
De Vries, TJ; de Vries, W; Diergaarde, L; Raasø, H; Schoffelmeer, AN	1
Gorzalka, BB; Hill, MN	1
Deissenrieder, F; Groneberg, D; Kusma, B; Mache, S; Quarcoo, D; Welte, T	1
Bhat, A; Crain, D	1
Coen, KM; Gamaleddin, I; Goldberg, SR; Le Foll, B; Makryannis, A; Vemuri, K; Wertheim, C; Zhu, AZ	1
Cohen, C; Griebel, G; Perrault, G; Soubrié, P	1
Heinzl, S	1
Camarelles Guillem, F	1
Shah, S; Tear, S	1
Tonstad, S	1
Frishman, WH	1
Anthenelli, RM	1
Foulds, J; Steinberg, MB	1
Damaj, MI; Lichtman, AH; Martin, BR; Merritt, LL; Walters, C	1
Aubin, HJ; Forget, B; Goldberg, SR; Le Foll, B	1
Buchhalter, AR; Fant, RV; Henningfield, JE	1

Reviews

6 review(s) available for sr141716 and Nicotine Addiction

Article	Year
[Endocannabinoid and endocannabinoid receptor antagonists]. Medizinische Monatsschrift fur Pharmazeuten, 2005, Volume: 28, Issue:2 Topics: Anti-Obesity Agents; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Clinical Trials as Topic; Endocannabinoids; Humans; Obesity; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant; Tobacco Use Disorder	2005
Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2006, Volume: 16, Issue:2 Topics: Cannabinoid Receptor Antagonists; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Metabolic Syndrome; Obesity; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome; Weight Gain	2006
Smoking cessation pharmacotherapy--nicotine and non-nicotine preparations. Preventive cardiology, 2007,Spring, Volume: 10, Issue:2 Suppl 1 Topics: Administration, Cutaneous; Administration, Inhalation; Benzazepines; Bupropion; Chewing Gum; Clonidine; Coronary Artery Disease; Humans; Monoamine Oxidase Inhibitors; Nicotine; Nortriptyline; Piperidines; Pyrazoles; Quinoxalines; Receptors, Nicotinic; Rimonabant; Selective Serotonin Reuptake Inhibitors; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder; Tobacco, Smokeless; Varenicline	2007
Rimonabant for treating tobacco dependence. Vascular health and risk management, 2007, Volume: 3, Issue:3 Topics: Animals; Cannabinoid Receptor Modulators; Humans; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Smoking; Smoking Cessation; Tobacco Use Disorder	2007
Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies. Addiction biology, 2008, Volume: 13, Issue:2 Topics: Animals; Brain; Cannabinoid Receptor Modulators; Clinical Trials as Topic; Drug Evaluation, Preclinical; Emotions; Humans; Motivation; Nicotine; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Secondary Prevention; Smoking Cessation; Tobacco Use Disorder	2008
Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status. Drugs, 2008, Volume: 68, Issue:8 Topics: Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Clonidine; Cytochrome P-450 CYP2A6; Drug Delivery Systems; GABA Modulators; Humans; Narcotic Antagonists; Nicotine; Piperidines; Pyrazoles; Receptors, Nicotinic; Rimonabant; Substance Withdrawal Syndrome; Tobacco Use Disorder; Vaccination	2008

Other Studies

14 other study(ies) available for sr141716 and Nicotine Addiction

Article	Year
Attenuation of cue-induced reinstatement of nicotine seeking by URB597 through cannabinoid CB1 receptor in rats. Psychopharmacology, 2016, Volume: 233, Issue:10 Topics: Amidohydrolases; Animals; Arachidonic Acids; Benzamides; Cannabinoid Receptor Antagonists; Carbamates; Cues; Drug-Seeking Behavior; Endocannabinoids; Male; Nicotine; Piperidines; Polyunsaturated Alkamides; PPAR alpha; Pyrazoles; Rats; Rats, Long-Evans; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Tobacco Use Disorder	2016
Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel Monkeys. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2016, Volume: 41, Issue:9 Topics: Animals; Conditioning, Operant; Cues; Dronabinol; Drug-Seeking Behavior; Male; Marijuana Abuse; Nicotine; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Recurrence; Reinforcement, Psychology; Rimonabant; Saimiri; Self Administration; Tobacco Use Disorder	2016
The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability. The international journal of neuropsychopharmacology, 2016, Volume: 19, Issue:12 Topics: Animals; Anxiety; Behavior, Addictive; Behavior, Animal; Cannabinoid Receptor Antagonists; Cues; Depression; Disease Models, Animal; Dopaminergic Neurons; Dose-Response Relationship, Drug; Drug Inverse Agonism; Drug-Seeking Behavior; Male; Maze Learning; Mesencephalon; Motivation; Motor Activity; Piperidines; Pyrazoles; Rats, Long-Evans; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction; Swimming; Time Factors; Tobacco Use Cessation Devices; Tobacco Use Disorder; Weight Loss	2016
Contextual renewal of nicotine seeking in rats and its suppression by the cannabinoid-1 receptor antagonist Rimonabant (SR141716A). Neuropharmacology, 2008, Volume: 55, Issue:5 Topics: Analysis of Variance; Animals; Behavior, Animal; Cannabinoid Receptor Antagonists; Conditioning, Operant; Extinction, Psychological; Male; Nicotine; Piperidines; Pyrazoles; Rats; Rats, Wistar; Reinforcement, Psychology; Rimonabant; Self Administration; Tobacco Use Disorder	2008
Impairments in endocannabinoid signaling and depressive illness. JAMA, 2009, Mar-18, Volume: 301, Issue:11 Topics: Affect; Anti-Obesity Agents; Antidepressive Agents; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Depression; Depressive Disorder; Endocannabinoids; Humans; Ligands; Obesity; Piperidines; Pyrazoles; Research; Rimonabant; Signal Transduction; Tobacco Use Disorder	2009
[Current and future medical drugs for smoking cessation]. Laryngo- rhino- otologie, 2009, Volume: 88, Issue:6 Topics: Adrenergic alpha-Agonists; Antidepressive Agents; Behavior Therapy; Benzazepines; Bupropion; Cannabinoid Receptor Antagonists; Clinical Trials as Topic; Clonidine; Combined Modality Therapy; Counseling; Humans; Nicotine; Nicotinic Agonists; Nortriptyline; Piperidines; Pyrazoles; Quinoxalines; Rimonabant; Smoking Cessation; Tobacco Use Disorder; Vaccines; Varenicline	2009
Current treatment options in smoking cessation. Hospital practice (1995), 2010, Volume: 38, Issue:1 Topics: Adrenergic alpha-Agonists; Antidepressive Agents; Behavior Therapy; Benzazepines; Bupropion; Clonidine; Combined Modality Therapy; Counseling; Humans; Nicotine; Nicotinic Agonists; Nortriptyline; Patient Selection; Piperidines; Practice Guidelines as Topic; Pyrazoles; Quinoxalines; Rimonabant; Self-Help Groups; Smoking Cessation; Tobacco Use Disorder; United States; Vaccines; Varenicline	2010
Cannabinoid receptor stimulation increases motivation for nicotine and nicotine seeking. Addiction biology, 2012, Volume: 17, Issue:1 Topics: Analgesics, Opioid; Animals; Behavior, Addictive; Behavior, Animal; Benzoxazines; Conditioning, Operant; Cues; Discrimination, Psychological; Dose-Response Relationship, Drug; Extinction, Psychological; Feeding Behavior; Male; Morpholines; Motivation; Motor Activity; Naphthalenes; Nicotine; Piperidines; Pyrazoles; Rats; Rats, Long-Evans; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Reinforcement, Psychology; Rimonabant; Self Administration; Tobacco Use Disorder	2012
Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2005, Volume: 30, Issue:1 Topics: Acoustic Stimulation; Animals; Cues; Dopamine; Environment; Extinction, Psychological; Light; Male; Motivation; Motor Activity; Nicotine; Nicotinic Agonists; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Self Administration; Substance Withdrawal Syndrome; Synaptic Transmission; Tobacco Use Disorder	2005
[Blocking cannabinoid receptors. Simultaneous control of overweight and nicotine addiction]. MMW Fortschritte der Medizin, 2004, Mar-04, Volume: 146, Issue:10 Topics: Appetite; Body Weight; Brain; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome	2004
[Medication for ending tobacco dependency. Current state]. Atencion primaria, 2005, Jun-30, Volume: 36, Issue:2 Topics: Antidepressive Agents, Second-Generation; Benzazepines; Bupropion; Cannabinoid Receptor Antagonists; Humans; Nicotine; Piperidines; Pyrazoles; Quinoxalines; Receptors, Nicotinic; Rimonabant; Smoking Cessation; Time Factors; Tobacco Use Disorder; Varenicline	2005
Tackling obesity and nicotine dependence. IDrugs : the investigational drugs journal, 2005, Volume: 8, Issue:12 Topics: Animals; Humans; Immunotherapy; Indoles; Obesity; Piperidines; Pyrazoles; Rimonabant; Serotonin Antagonists; Smoking Cessation; Tobacco Use Disorder	2005
A call to action: new treatment options provide even more reasons to intervene in tobacco dependence. Nature clinical practice. Cardiovascular medicine, 2007, Volume: 4, Issue:9 Topics: Benzazepines; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Obesity; Piperidines; Prevalence; Pyrazoles; Quinoxalines; Rimonabant; Risk Factors; Smoking; Smoking Cessation; Tobacco Use Disorder; Varenicline	2007
The endogenous cannabinoid system modulates nicotine reward and dependence. The Journal of pharmacology and experimental therapeutics, 2008, Volume: 326, Issue:2 Topics: Animals; Cannabinoid Receptor Modulators; Conditioning, Psychological; Female; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Nicotine; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Reward; Rimonabant; Signal Transduction; Substance Withdrawal Syndrome; Tobacco Use Disorder	2008